Yasmin review extension
This article was originally published in Pharmaceutical Approvals Monthly
FDA's user fee deadline for a low-dose version of Schering AG's oral contraceptive Yasmin (ethinyl estradiol/drospirenone) is Nov. 16 following a three-month review extension. "According to the FDA's written notification to [U.S. subsidiary] Berlex…the extension 'will provide time for a full review' of the application," Schering AG reported July 19. The firm said it "is confident in a 2005 launch" for the product, which contains 0.02 mg of estradiol compared to 0.03 mg in currently available Yasmin. A 2004 launch was projected at the time of the October 2003 filing...
You may also be interested in...
Cipla has expanded its partnership with Alvotech to cover the commercialization of five biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.
Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.
From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.